JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

UNH

305.4

+12.42%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

UNH

305.4

+12.42%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

UNH

305.4

+12.42%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

UNH

305.4

+12.42%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

UNH

305.4

+12.42%↑

Search

Eli Lilly and Co.

Uždarymo kaina

SektoriusSveikatos priežiūra

701.97 2.52

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

699

Max

705.33

Pagrindiniai rodikliai

By Trading Economics

Pajamos

2.9B

5.7B

Pardavimai

2.8B

16B

P/E

Sektoriaus vid.

41.436

34.427

Pelnas, tenkantis vienai akcijai

6.31

Dividendų pajamingumas

0.9

Pelno marža

36.384

Darbuotojai

47,000

EBITDA

3.3B

7.5B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+33.61% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.90%

2.47%

Kitas uždarbis

2025-10-30

Kitas dividendų mokėjimo data

2025-09-10

Kita Ex Dividend data

2025-11-14

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-121B

569B

Ankstesnė atidarymo kaina

699.45

Ankstesnė uždarymo kaina

701.97

Naujienos nuotaikos

By Acuity

40%

60%

121 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Eli Lilly and Co. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-07 11:36; UTC

Uždarbis

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand

2025-08-12 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

2025-08-08 19:34; UTC

Rinkos pokalbiai

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

2025-08-08 05:32; UTC

Rinkos pokalbiai

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

2025-08-07 16:20; UTC

Uždarbis

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

2025-08-07 14:18; UTC

Rinkos pokalbiai
Uždarbis

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

2025-08-07 13:54; UTC

Uždarbis

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

2025-08-07 12:12; UTC

Uždarbis

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

2025-08-07 11:58; UTC

Uždarbis

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

2025-08-07 11:32; UTC

Uždarbis

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

2025-08-07 11:03; UTC

Uždarbis

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

2025-08-07 10:49; UTC

Uždarbis

Eli Lilly 2Q Gross Margin 84.3% >LLY

2025-08-07 10:48; UTC

Uždarbis

Eli Lilly 2Q Volume Rose 42%, Realized Prices Fell 6% >LLY

2025-08-07 10:47; UTC

Uždarbis

Eli Lilly Raises 2025 Adjusted Performance Margin View to 43%-44.5% From 41.5%-43.5% >LLY

2025-08-07 10:46; UTC

Uždarbis

Eli Lilly Had Seen 2025 Adjusted EPS $20.78-$22.28 >LLY

2025-08-07 10:46; UTC

Uždarbis

Eli Lilly Had Seen 2025 Revenue $58B-$61B >LLY

2025-08-07 10:46; UTC

Uždarbis

Eli Lilly Raises 2025 View To Rev $60B-$62B >LLY

2025-08-07 10:45; UTC

Uždarbis

Eli Lilly 2Q Net $5.66B >LLY

2025-08-07 10:45; UTC

Uždarbis

Eli Lilly 2Q Rev $15.56B >LLY

2025-08-07 10:45; UTC

Uždarbis

Eli Lilly Sees FY Adj EPS $21.75-Adj EPS $23.00 >LLY

2025-08-07 10:41; UTC

Uždarbis

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

2025-08-06 20:34; UTC

Uždarbis

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

2025-08-06 08:45; UTC

Uždarbis

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

2025-07-30 10:38; UTC

Rinkos pokalbiai

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

2025-07-29 17:05; UTC

Uždarbis

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

2025-07-29 16:55; UTC

Uždarbis

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

2025-07-29 13:35; UTC

Uždarbis

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

2025-07-29 11:39; UTC

Uždarbis

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

2025-07-25 12:49; UTC

Įsigijimai, susijungimai, perėmimai

Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

2025-07-24 12:02; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly Expects to Complete Verve Acquisition on July 25 >LLY VERV

Akcijų palyginimas

Kainos pokytis

Eli Lilly and Co. Prognozė

Kainos tikslas

By TipRanks

33.61% į viršų

12 mėnesių prognozė

Vidutinis 936.89 USD  33.61%

Aukščiausias 1,190 USD

Žemiausias 715 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Eli Lilly and Co. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

21 ratings

17

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 884.54Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

121 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.